Brief: Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II
18/08/2025 23:13
Aug 18 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO ANNOUNCES FDA REVIEW EXTENSION OF BLA FOR RGX-121 TO TREAT PATIENTS WITH MPS II REGENXBIO INC - PDUFA DATE EXTENDED TO FEBRUARY 8, 2026 Source text: ID:nPn5DTxK3a Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics